Blog
When Early Decisions Shape Late-Stage Risk
Early clinical decisions shape regulatory risk and the path to approval Assumptions about study design and real-world execution don’t […]
Explore Insights
Find what matters to you
Read More
Blog
The Cohesion Museum Convergence
Four scientific principles. One unifying concept. The Cohesion Effect experience. SCOPE Summit is a place where innovation thrives. Thousands of […]
Blog
The Sponsor and CRO Symbiosis Effect: How cohesion carried us through a high-pressure NDA
When Tonix came to us, the stakes were high, and the timelines were tight. Their goal? To submit a New […]
Blog
The CRO Decoder: What Site-Centric Really Means (And What it Doesn’t)
Every CRO out there will tell you they’re site-centric, and on pitch decks, they use the right buzzwords to prove […]
Blog
The Lean Team Playbook: How small biotechs can nail ICH E6(R3) without a large QA team
You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team, a looming trial, […]
Guides
The R3 Timewarp Redemption: Preventable risks and how to avoid them in a trial
Picture this: a complex trial is running, but it has been plagued with issues from the start. From multiple delays […]
Blog
The MythBusters Revelations: Debunking compliance myths to keep your trial on track
ICH E6(R3) is here, and with it, clinical teams are bracing for the impacts. Biotechs are being asked to develop […]
Case Study
The Site Cohesion Hypothesis: 3 examples of the impact of CRO site relationships
Behind every enrollment milestone is a web of relationships—some strong, some strained, and some that make all the difference. At […]
Guides
The Site Stickiness Hypothesis: Good site relationships pay dividends
Every CRO claims to value sites. But the true nature of their site relationships could determine the outcome of your […]
Blog
Reform of the European Union Pharmaceutical Legislation (Adoption Stage TBD)
On 26 April 2023, the European Commission (EC) proposed reforming the European Union (EU) pharmaceutical legislation. This revision constitutes the first major overhaul of the pharmaceutical legislation since 2004. It will adapt the legislation to the needs of the 21st century.